<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">895159</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2022.895159</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification of an Au(I) N-Heterocyclic Carbene Compound as a Bactericidal Agent Against <italic>Pseudomonas aeruginosa</italic>
</article-title>
<alt-title alt-title-type="left-running-head">Wang et al.</alt-title>
<alt-title alt-title-type="right-running-head">Metal-Based Antibacterial Agents</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jinhui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Xiaoshuai</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Yanxuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Long</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Huowen</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1718458/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>He</surname>
<given-names>Xiaojun</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1718453/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zou</surname>
<given-names>Taotao</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mao</surname>
<given-names>Zong-Wan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/828835/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xia</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1298394/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Chemistry</institution>, <institution>Sun Yat-sen University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Ophthalmology and Optometry</institution>, <institution>School of Biomedical Engineering</institution>, <institution>Wenzhou Medical University</institution>, <addr-line>Wenzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>School of Pharmaceutical Sciences</institution>, <institution>Sun Yat-sen University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/865409/overview">Zhe Liu</ext-link>, Qufu Normal University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1719322/overview">Zhi Su</ext-link>, Nanjing Normal University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1728593/overview">Xinxin Feng</ext-link>, Hunan University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xiaojun He, <email>hexiaojun2008@163.com</email>; Taotao Zou, <email>zoutt3@mail.sysu.edu.cn</email>; Zong-Wan Mao, <email>cesmzw@mail.sysu.edu.cn</email>; Wei Xia, <email>xiawei5@mail.sysu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Inorganic Chemistry, a section of the journal Frontiers in Chemistry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>895159</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>03</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wang, Sun, Xie, Long, Chen, He, Zou, Mao and Xia.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Sun, Xie, Long, Chen, He, Zou, Mao and Xia</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The opportunistic pathogen <italic>Pseudomonas aeruginosa</italic> (<italic>P. aeruginosa</italic>) causes infections that are difficult to treat, which is due to the bacterial resistance to antibiotics. We herein identify a gold(I) N-heterocyclic carbene compound as a highly potent antibacterial agent towards <italic>P. aeruginosa</italic>. The compound significantly attenuates <italic>P. aeruginosa</italic> virulence and leads to low tendency to develop bacterial resistance. The antibacterial mechanism studies show that the compound abrogates bacterial membrane integrity, exhibiting a high bactericidal activity toward <italic>P. aeruginosa</italic>. The relatively low cytotoxic compound has excellent therapeutic effects on both the eukaryotic cell co-culture and murine wound infection experiments, suggesting its potential application as a bactericidal agent to combat <italic>P. aeruginosa</italic> infection.</p>
</abstract>
<kwd-group>
<kwd>gram-negative</kwd>
<kwd>
<italic>Pseudomonas aeruginosa</italic>
</kwd>
<kwd>antibacterial agents</kwd>
<kwd>Au(I) N-heterocyclic carbene compound</kwd>
<kwd>bactericidal activity</kwd>
<kwd>bacterial resistance</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>
<italic>Pseudomonas aeruginosa</italic> (<italic>P. aeruginosa</italic>) is a Gram-negative bacterium that exhibits extensive metabolic adaptability, enabling it to thrive in an extensive range of niches. It perfectly evolved to be a successful opportunistic pathogen, causing wide range of acute, and chronic infections (<xref ref-type="bibr" rid="B31">Mah et al., 2003</xref>; <xref ref-type="bibr" rid="B44">Wu et al., 2011</xref>; <xref ref-type="bibr" rid="B30">Lund-Palau and Turnbull, 2016</xref>; <xref ref-type="bibr" rid="B23">Lee and Yoon, 2017</xref>). For example, patients with cystic fibrosis (CF) or immunodeficiency are peculiarly susceptible to the <italic>P. aeruginosa</italic> infections (<xref ref-type="bibr" rid="B37">Shteinberg et al., 2021</xref>). <italic>P. aeruginosa</italic> has inherent resistance to a series of antibiotics through various mechanisms, such as reducing outer membrane permeability, expression of efflux systems that pump antibiotics out of the cell (<xref ref-type="bibr" rid="B20">J&#xfc;rg and Paolo, 2015</xref>; <xref ref-type="bibr" rid="B40">Verch&#xe8;re et al., 2015</xref>). Moreover, <italic>P. aeruginosa</italic> can acquire drug resistance by either horizontal transfer of resistance genes or mutational changes (<xref ref-type="bibr" rid="B3">Botelho et al., 2019</xref>; <xref ref-type="bibr" rid="B17">Hernando-Amado et al., 2020</xref>). Therefore, the infections caused by this organism are notoriously difficult to treat. Thus, there is an urgent need for the development of new antimicrobial reagents with distinct mechanism of action to combat <italic>P. aeruginosa</italic> infection (<xref ref-type="bibr" rid="B33">Martin et al., 2020</xref>; <xref ref-type="bibr" rid="B35">Mitcheltree et al., 2021</xref>).</p>
<p>Metal-containing compounds have exerted a seminal role in medicinal chemistry. A series of metal complexes are currently in clinical use for the treatment of bacterial infections (<xref ref-type="bibr" rid="B6">Chernousova and Epple, 2013</xref>; <xref ref-type="bibr" rid="B9">Fischbach and Malfertheiner, 2018</xref>). These metal compounds usually have unique mechanism of action, such as ligand exchange or release, reactive oxygen species (ROS) generation (<xref ref-type="bibr" rid="B26">Liao et al., 2017a</xref>; <xref ref-type="bibr" rid="B16">He et al., 2017</xref>; <xref ref-type="bibr" rid="B14">Han et al., 2018</xref>). Particularly, these metal compounds have multi-target properties to inhibit bacterial growth and thereby reducing the development of drug resistance of bacteria when compared with the conventional antibiotics (<xref ref-type="bibr" rid="B12">Gasser and Metzler-Nolte, 2012</xref>; <xref ref-type="bibr" rid="B10">Frei et al., 2020</xref>). Recent studies on drug repositioning led to the discovery of auranofin, a drug initially approved as an anti-rheumatic agent, exhibiting potent antibacterial activity (<xref ref-type="bibr" rid="B15">Harbut et al., 2015</xref>; <xref ref-type="bibr" rid="B39">Thangamani et al., 2016</xref>; <xref ref-type="bibr" rid="B29">Lu et al., 2020</xref>; <xref ref-type="bibr" rid="B38">Sun et al., 2020</xref>). Auranofin is active against a broad-spectrum of Gram-positive bacteria via inhibition of the thioredoxin reductase, thereby sensitizing the bacteria to oxidative stress (<xref ref-type="bibr" rid="B15">Harbut et al., 2015</xref>). Although auranofin showed promise for treatment of infectious diseases caused by Gram-positive bacteria, the metal compound lacked bactericidal activity toward Gram-negative bacteria, impeding its practical application.</p>
<p>Herein, we reported that a mononuclear gold compound, NHC<sup>Me</sup>-Au-Cl (NHC &#x3d; N-heterocyclic carbene), named as Au1, exhibited high bactericidal activities to both Gram-negative and Gram-positive bacteria. Similar to auranofin, Au1 could significantly inhibit the virulence factors of <italic>P. aeruginosa</italic>. Importantly, repeated use of the gold compound does not lead to bacterial drug resistance. Moreover, the treatment of Au1 led to severe bacterial membrane crumpling, and thereby disrupted the membrane integrity of <italic>P. aeruginosa</italic>. Further transcriptomic and proteomic analysis showed that Au1 and auranofin have different mechanism of action. Au1 substantially disturbed the trehalose biosynthesis and riboflavin metabolism pathways in <italic>P. aeruginosa</italic>. The anti-bacterial activities of <bold>Au1</bold> were further verified <italic>in vivo</italic> using murine skin infection experiments. Our studies revealed the potential of the <bold>Au1</bold> compound as a novel bactericidal reagent to combat the <italic>P. aeruginosa</italic> infections.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Gold(I) Compound Preparation</title>
<p>Au4 and Au9 (auranofin) are purchased from Sigma-Aldrich. Au1&#x2013;Au3 (<xref ref-type="bibr" rid="B18">Hickey et al., 2008</xref>; <xref ref-type="bibr" rid="B28">Long et al., 2021</xref>), four dinuclear gold(I)-phosphine compounds Au5&#x2013;Au8 (<xref ref-type="bibr" rid="B5">Che et al., 1990</xref>; <xref ref-type="bibr" rid="B11">Fu et al., 1999</xref>; <xref ref-type="bibr" rid="B19">Igashira-Kamiyama et al., 2013</xref>; <xref ref-type="bibr" rid="B46">Zou et al., 2014</xref>) and two auranofin derivatives Au10&#x2013;Au11 (<xref ref-type="bibr" rid="B1">Baker et al., 2005</xref>) were synthesized and characterized as previously described.</p>
</sec>
<sec id="s2-2">
<title>Bacterial Strains and Growth Condition</title>
<p>
<italic>Pseudomonas aeruginosa</italic> strain PAO1 (<italic>P. aeruginosa</italic>) was grown in M9 minimal medium (1.0&#xa0;g/L NH<sub>4</sub>Cl, 0.5&#xa0;g/L NaCl, 6.0&#xa0;g/L Na<sub>2</sub>HPO<sub>4</sub>, 3.0&#xa0;g/L KH<sub>2</sub>PO<sub>4</sub>) supplemented with 1.0&#xa0;mM MgSO<sub>4</sub>, 1.0&#xa0;mM ZnSO<sub>4</sub>, 0.2&#xa0;mM CaCl<sub>2</sub>, 0.4% (w/v) glucose and 0.2% (w/v) casein hydrolysate. <italic>Gram</italic>-negative <italic>Escherichia coli</italic> strain K-12 (<italic>E. coli</italic>) and <italic>Burkholderia cepacia J2315</italic> (<italic>B. cepacia</italic>) were cultured in Luria-Bertani (LB) medium (5&#xa0;g/L yeast extract, 10&#xa0;g/L tryptone, 10&#xa0;g/L sodium chloride). The <italic>Gram</italic>-positive <italic>Staphylococcus aureus</italic> strain Newman (<italic>S. aureus</italic>) was grown in Tryptic Soy Broth (TSB) medium (17&#xa0;g/L Tryptone, 3&#xa0;g/L Phytone, 5&#xa0;g/L sodium chloride, 2.5&#xa0;g/L dipotassium phosphate and glucose 2.5&#xa0;g/L).</p>
</sec>
<sec id="s2-3">
<title>Antimicrobial Activity</title>
<p>The minimal inhibitory concentration (MIC) values of the gallium compounds were determined using a standard broth dilution method as described previously (<xref ref-type="bibr" rid="B43">Wiegand et al., 2008</xref>). In brief, the compounds were two-fold serially diluted to concentrations from 400 to 1.56&#xa0;&#x3bc;M. Approximately 50&#xa0;&#x3bc;L of the compound solution was added to a 96-well microtiter plate and mixed with 50&#xa0;&#x3bc;L of bacteria culture in log phase (10<sup>6</sup> CFU/ml). The bacterial culture was further incubated at 37&#xb0;C for 22&#x2013;24&#xa0;h. The OD<sub>600</sub> values for each well was recorded on a microplate reader. The MICs value was defined as the lowest compound concentration that inhibited 95% of the bacterial growth.</p>
</sec>
<sec id="s2-4">
<title>Cytotoxicity in Mammalian Cell</title>
<p>The cytotoxicity of gold compounds to mammalian cells was measured using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Human hepatocyte L-O2 cell, and lung carcinoma A549 cell were cultured in Corning 96 well microplates (10<sup>4</sup> cells per well) at 37&#xb0;C for 18&#xa0;h. Then the cells were incubated with gradient concentrations of gold compounds at 37&#xb0;C for another 48&#xa0;h. After the treatment, cell culture media were removed and the plates were wash with PBS for three times. And 90&#xa0;&#x3bc;L fresh media and 10&#xa0;&#x3bc;L 5&#xa0;mg/ml MTT solution were added to each well and further incubated at 37&#xb0;C for 4&#xa0;h. Subsequently, the media were removed from the wells and 150&#xa0;&#x3bc;L DMSO was added into each well to dissolve the formazan crystals. The absorbance at 490&#xa0;nm of each well was measured with a micro-plate reader. The experiments were carried out in triplicates.</p>
</sec>
<sec id="s2-5">
<title>Measurement of Au Contents</title>
<p>The amount of gold compound uptake by <italic>P. aeruginosa</italic> was quantified by ICP-MS. <italic>P. aeruginosa</italic> overnight culture was diluted to OD<sub>600</sub> of 0.1 in the presence of 15&#xa0;&#x3bc;M of <bold>Au1</bold> or auranofin. Approximately 5&#xa0;ml aliquot of bacterial culture was removed and collected every 2&#xa0;h, up to 8&#xa0;h. After washing with cold PBS supplemented with 5&#xa0;mM EDTA (Sigma-Aldrich), cell pellets were digested with 70% HNO<sub>3</sub> at 60&#xb0;C overnight. Samples were then diluted with ddH<sub>2</sub>O to a final concentration of ca. 5% HNO<sub>3</sub> and analyzed by ICP-MS (iCAP RQ, Thermo Fisher).</p>
</sec>
<sec id="s2-6">
<title>Drug Resistance Development Assay</title>
<p>Development of resistance to the Au1 compound and the antibiotics (ciprofloxacin and tobramycin) were assessed as described by <xref ref-type="bibr" rid="B13">Habets and Brockhurst (2012)</xref>. The MIC assay was performed on the first day as described above. On the next day, the MIC was recorded as the minimal concentration that completely inhibited growth. Thereafter, a new passage MIC measurement assay was prepared using diluted bacterial cells grown at 0.5-fold MIC suspension. This was repeated for 14 passages and the MIC values for Au1, ciprofloxacin and tobramycin were recorded for each passage.</p>
</sec>
<sec id="s2-7">
<title>Quantification of Bacterial Virulence Factors</title>
<p>To quantify the secreted virulence factors, overnight <italic>P. aeruginosa</italic> PAO1 was diluted in fresh M9 medium and cultured to a final OD<sub>600</sub> value of 0.15. Then Au1 or auranofin were added into culture with indicated concentrations. After 24&#xa0;h incubation at 37&#xb0;C, the bacterial supernatants were collected by centrifugation at 4,000&#xa0;g for 10&#xa0;min at 4&#xb0;C and filtered using a 0.22&#xa0;&#x3bc;m syringe filter (Millipore). The secreted virulence factors in the supernatant were quantified by the methods described below.</p>
<p>For LasA protease detection, 5&#xa0;&#x3bc;L of filtered supernatant was mixed with 1&#xa0;ml of 0.5% azocasein (Sigma-Aldrich) in reaction buffer (50&#xa0;mM Tris-HCl, 0.5&#xa0;mM CaCl<sub>2</sub>, pH 7.5). The mixture was incubated at 37&#xb0;C for 15&#xa0;min. After reaction, 500&#xa0;&#x3bc;L of 10% trichloroacetic (TCI Shanghai) acid was added and incubated for 30&#xa0;min at room temperature. After centrifugation at 10,000&#xa0;g for 20&#xa0;min, the 440&#xa0;nm absorbance of the collected supernatant was measured to quantify the secreted LasA protease.</p>
<p>The LasB elastase was examined by Elastin-Congo red assay (<xref ref-type="bibr" rid="B36">Morihara et al., 1965</xref>). In brief, 700&#xa0;&#x3bc;L of bacterial supernatant was incubated with 700&#xa0;&#x3bc;L of 10&#xa0;mg/ml Elastin-Congo (Sigma-Aldrich) red elastase substrate in reaction buffer (100&#xa0;mM Tris-HCl, 1&#xa0;mM CaCl<sub>2</sub>, pH 7.5) at 37&#xb0;C for 3&#xa0;h with shaking. Then 0.2&#xa0;ml EDTA was added to a final concentration of 10&#xa0;mM to stop the cleavage reaction. Insoluble pellets were removed by centrifugation and the absorbance of the supernatant at 495&#xa0;nm was measured.</p>
<p>The bacterial secreted pyocyanin was quantified as described previously (<xref ref-type="bibr" rid="B8">Essar et al., 1990</xref>). Approximately 10&#xa0;ml bacterial supernatant medium was collected by centrifugation. Subsequently, 3&#xa0;ml chloroform was added into medium to extract the pyocyanin. The pyocyanin was re-extracted into 1&#xa0;ml of 0.2&#xa0;M HCl to give a pink to deep red solution after approximately 30&#xa0;min. The pyocyanin concentration was determined by measurement the absorbance at 520&#xa0;nm.</p>
<p>For rhamnolipid measurement, rhamnolipid was extracted from the supernatant with a mixture of chloroform and methanol (v:v &#x3d; 2:1). The organic solvent phase was then evaporated to dryness and 100&#xa0;&#x3bc;L methanol was added to dissolve the extracted rhamnolipid. Then 200&#xa0;&#x3bc;L of pre-cooled anthrone solution (dissolving 2&#xa0;g of anthrone in 1&#xa0;L of concentrated H<sub>2</sub>SO<sub>4</sub>) was added into 20&#xa0;&#x3bc;L extracted rhamnolipid sample and heat at 80&#xb0;C for 30min. The rhamnolipid concentration was determined by measurement the absorbance at 630&#xa0;nm.</p>
</sec>
<sec id="s2-8">
<title>
<italic>P. aeruginosa</italic> Biofilm Inhibition</title>
<p>
<italic>P. aeruginosa</italic> was cultured in 24-well microtiter plate (Corning, NY, United States) for static biofilm formation. For biofilm inhibition assay, approximately 1&#xa0;ml of bacterial overnight culture were diluted in fresh M9 medium with a final OD<sub>600</sub> value of 0.33 and transferred into each well of microtiter plate in the absence or presence of sub-lethal concentration of Au1 or auranofin (2.5, 10, and 15&#xa0;&#x3bc;M). After static incubation at 37&#xb0;C for 48&#xa0;h, weakly adherent planktonic cells were removed from the microtiter plate by washing with phosphate buffered saline (PBS) for three times gently. The adherent biofilms were dried and stained with 0.1% (w/v) crystal violet for 15&#xa0;min. Excess dye was removed by rinsing the plate three times with PBS. Crystal violet was solubilized from the stained biofilms by adding 30% acetic acid and the biofilms were quantified by measuring the 595&#xa0;nm absorbance. Each experiment was performed in triplicates.</p>
</sec>
<sec id="s2-9">
<title>Field Emission Scanning Electron Microscopy</title>
<p>Images of <italic>P. aeruginosa</italic> were recorded on a JSM-6330F (JEOL) field emission scanning electron microscopy as previously reported (<xref ref-type="bibr" rid="B45">Zhao et al., 2021</xref>). <italic>P. aeruginosa</italic> was cultured in M9 medium until OD<sub>600</sub> reached 0.6&#x2013;0.8. Au1 or auranofin was added to medium to a final concentration of 50&#xa0;&#xb5;M and further incubated at 37&#xb0;C for 1&#xa0;h with shaking. After washing twice with PBS buffer, the samples were subsequently fixed using 2.5% glutaraldehyde in PBS buffer at 4&#xb0;C overnight. After rinsing twice with PBS buffer, the samples were subsequently exposed to ethanol dehydration series of 30, 50, 70, 90% for 10&#xa0;min and 100% for 30&#xa0;min. All the samples were finally air-dried in a vacuum desiccator and sputter-coated with palladium-gold thin film before data collection.</p>
</sec>
<sec id="s2-10">
<title>Atomic Force Microscopy</title>
<p>For AFM imaging of bacterial cells, <italic>P. aeruginosa</italic> was cultured in M9 medium until OD<sub>600</sub> reached 0.6&#x2013;0.8. Au1 or auranofin was added to medium to a final concentration of 50&#xa0;&#xb5;M and further incubated at 37&#xb0;C for 1&#xa0;h. Diluted bacterial suspension was added on a dry glass slide that is pre-treated with poly-L-Lysine. After immobilization for 1&#xa0;h, excess liquid was removed and the glass slide was wash with PBS gently. Finally, dry glass slide was subjected to a Dimension FastScan<sup>&#xae;</sup> atomic force microscope (Bruker) with tapping mode.</p>
</sec>
<sec id="s2-11">
<title>Bacterial Membrane Permeability Assay</title>
<p>Overnight <italic>P. aeruginosa</italic> culture was diluted 1:100 with fresh M9 medium and grown to early-mid exponential phase (OD<sub>600</sub> &#x3d; 0.4&#x2013;0.6). The culture was then diluted 1:10 into PBS and treated with the 50&#xa0;&#x3bc;M concentration of Au1 or auranofin for 30&#xa0;min. Then the bacteria were incubated with propidium iodide (PI), a dye that is excluded from cells with impermeable membrane. The CytoFLEX flow cytometry (Beckman Coulter) was used to measure the bacterial fluorescent intensities and the data was analyzed using CytExpert 2.4 software. For the time-course detection of the bacterial permeability induced by Au1 or auranofin, <italic>P. aeruginosa</italic> in early-mid exponential phase (OD<sub>600</sub> &#x3d; 0.2) was incubated with PI dye on a 96-well plate. <bold>Au1</bold> or auranofin was added to a final concentration of 50&#xa0;&#x3bc;M. The fluorescence signal (561&#xa0;nm excitation, 590&#xa0;nm emission) and OD<sub>600</sub> value were recorded on Cytation5 microplate reader. Each experiment was performed in triplicates.</p>
</sec>
<sec id="s2-12">
<title>Transcriptomic Assay and Data Processing</title>
<p>
<italic>P. aeruginosa</italic> cultures were grown to early log phase (OD<sub>600</sub> &#x3d; 0.3) and Au1 (or auranofin) compound was added to a final concentration of 15&#xa0;&#x3bc;M and the bacteria were further cultured for 4&#xa0;h at 37&#xb0;C. And total RNA was isolated from the cultured <italic>P. aeruginosa</italic> cells using SV total RNA isolation kit (Promega) according to the manufacturer&#x2019;s instructions. And RNA was quantified by NanoDrop spectrophotometer. The quality of the isolated RNA was examined by Agilent 2,100 Bioanalyzer (Agilent). Paired-end, strand-specific RNA-seq was performed using the dUTP method (<xref ref-type="bibr" rid="B24">Levin et al., 2010</xref>). The ribosomal RNAs were removed with Ribo-Zero rRNA Removal Kit (Illumina). Subtracted RNAs were fragmented and reverse-transcribed. The sequencing library was loaded on an Illumina HiSeq instrument according to manufacturer&#x2019;s instruction. RNA-seq experiments were performed in triplicates.</p>
</sec>
<sec id="s2-13">
<title>Co-Culture Experiment</title>
<p>Human alveolar basal epithelial A549 cells were cultured in 1,640 medium. And Au1 was added into medium to different final concentrations (10, 20, and 30&#xa0;&#x3bc;M). <italic>P. aeruginosa</italic> overnight culture was diluted 10 times by 1,640 medium and incubated at 37&#xb0;C for 2&#xa0;h. Subsequently, the adapted <italic>P. aeruginosa</italic> bacterium was added into A549 cell culture to a final concentration of 10<sup>6</sup> CFU/ml and the culture was further incubated at 37&#xb0;C for 2&#xa0;h. The morphology of the cells was recorded on a Nikon eclipse TS100 inverted microscopy.</p>
</sec>
<sec id="s2-14">
<title>Mouse Skin Infection</title>
<p>Six-week-old female BALB/c mice were used for animal experiments to evaluate the healing effect of infected wounds <italic>in vivo</italic>. Briefly, mouse backs were cut to generate a circular wound (diameter 0.6&#xa0;cm) with a hole punch and the wound was infiltrated using a medical cotton swab with <italic>P. aureginosa</italic> (overnight culture, OD<sub>600</sub> &#x3d; 0.3). The mice were randomly divided into three groups, including PBS, auranofin, and Au-1 groups (n &#x3d; 5 in each group). The drugs were dissolved in DMSO and diluted with glycerol to a final concentration of 50&#xa0;&#x3bc;M. After the bacterial fluid was dry, about 20&#xa0;&#x3bc;L of the drug was added to the wound. Body weights and wound photography was recorded on days 0, 1, 3, 5, and 8. And on the 8th day, the mice were euthanized by chloral hydrate, the infectious tissues in all groups were collected and cultured into the LB plate for colony counting. The skin tissues were also fixed by paraformaldehyde solution (4%) for H&#x26;E, Gram, and Masson&#x2019;s trichrome staining.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Identification of Bactericidal Gold(I) Compounds</title>
<p>In total, eleven gold(I) compounds were used to examine the anti-bacterial activities against <italic>P. aeruginosa</italic> PAO1 strain (<xref ref-type="fig" rid="F1">Figure 1</xref>). These compounds included four mononuclear gold(I) compounds Au1&#x2013;Au4, four dinuclear gold(I)-phosphine compounds Au5&#x2013;Au8, auranofin (Au9) and two auranofin derivatives Au10&#x2013;Au11. The minimal inhibitory concentrations (MIC) of these compounds were shown in <xref ref-type="table" rid="T1">Table 1</xref>. All the mononuclear gold(I) carbene compounds exhibited substantial bactericidal activities toward <italic>P. aeruginosa</italic>, among which Au1 had the lowest MIC value of 25&#xa0;&#x3bc;M. Au2 that contains a larger NHC<sup>IPr</sup> carbene ligand, had a higher MIC value (100&#xa0;&#x3bc;M), indicative of the essential role of the NHC<sup>Me</sup> ligand for the bactericidal activity of gold compound. Unexpectedly, the four dinuclear gold(I)-phosphine compounds exhibited significantly different bactericidal activities. Au5 is highly toxic to the bacteria with a MIC value of 6.25&#xa0;&#x3bc;M. In contrast, Au6&#x2013;Au8 exhibited much weaker or no bactericidal activities. The high bactericidal activity of lipophilic Au5 is probably due to its enhanced cell permeability. However, increasing lipophilicity of Au6 and Au7 led to poor water solubility, which may partially explain their low antibacterial activities. Whereas, the instability of Au8 in solution might contribute to its low activity (<xref ref-type="bibr" rid="B2">Berners-Price and Sadler, 1986</xref>). In addition, the auranofin and two derivatives had no bactericidal activities toward <italic>P. aeruginosa</italic> with the MIC values higher than 400&#xa0;&#x3bc;M. In line with the determined MIC values, bacterial growth curves showed that the <italic>P. aeruginosa</italic> growth was completely inhibited in the presence of 20&#xa0;&#x3bc;M Au1 or 3&#xa0;&#x3bc;M Au5. In contrast, as high as 25&#xa0;&#x3bc;M aranofin exhibited little impact on the bacterial growth (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). Therefore, the mononuclear Au1 and dinuclear Au5 are the two most potent bactericidal gold compounds.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Chemical structure of the gold(I) compounds.</p>
</caption>
<graphic xlink:href="fchem-10-895159-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The minimal inhibitory concentrations (MIC) of Au1&#x2013;Au11 towards <italic>P. aeruginosa</italic>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound</th>
<th align="center">MIC (&#x3bc;M)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Au1</td>
<td align="char" char=".">25</td>
</tr>
<tr>
<td align="left">Au2</td>
<td align="char" char=".">100</td>
</tr>
<tr>
<td align="left">Au3</td>
<td align="char" char=".">100</td>
</tr>
<tr>
<td align="left">Au4</td>
<td align="char" char=".">100</td>
</tr>
<tr>
<td align="left">Au5</td>
<td align="char" char=".">6.25</td>
</tr>
<tr>
<td align="left">Au6</td>
<td align="char" char=".">200</td>
</tr>
<tr>
<td align="left">Au7</td>
<td align="char" char=".">&#x3e;400</td>
</tr>
<tr>
<td align="left">Au8</td>
<td align="char" char=".">&#x3e;400</td>
</tr>
<tr>
<td align="left">Au9</td>
<td align="char" char=".">&#x3e;400</td>
</tr>
<tr>
<td align="left">Au10</td>
<td align="char" char=".">&#x3e;400</td>
</tr>
<tr>
<td align="left">Au11</td>
<td align="char" char=".">400</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Subsequently, the mammalian cell cytotoxicity of Au1, Au5, and auranofin were examined using A549 and LO2 cell lines. The MTT assays showed that Au5 and auranofin had high cytotoxicity to A549 cell, with the IC<sub>50</sub> values of 1.7 &#xb1; 0.2 and 2.8 &#xb1; 0.4&#xa0;&#x3bc;M, respectively. While the cytotoxicity of Au1 is much lower with an IC<sub>50</sub> value of 32.8 &#xb1; 1.6&#xa0;&#x3bc;M. Similar results were also obtained for the LO2 cells (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>). Given the high bactericidal activity and relatively low cytotoxicity of Au1, we then focused on Au1 and characterized its antibacterial activity.</p>
</sec>
<sec id="s3-2">
<title>Characterization of the Antibacterial Activity of Au1</title>
<p>Although <bold>Au1</bold> can effectively eliminate <italic>P. aeruginosa,</italic> the N-heterocyclic carbine ligand had no effect on bacterial growth even at 50&#xa0;&#x3bc;M, indicating that the intact compound structure is required for the high bactericidal activity (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). We subsequently examined the antibacterial activities of Au1 against other common bacterial species, including <italic>Staphylococcus aureus Newman</italic>, <italic>Burkholderia cepacia J2315</italic> and <italic>Escherichia coli MG16552</italic>. The sensitivity of these pathogens to Au1 compound and four antibiotics were investigated (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). The results showed that Au1 exhibited broad-spectrum antibacterial activities against all the four bacteria species, which is comparable to the ciprofloxacin.</p>
<p>Previous studies indicated that the low bactericidal activity of auranofin was due to the two-membrane barrier of Gram-negative bacteria (<xref ref-type="bibr" rid="B4">Breijyeh et al., 2020</xref>; <xref ref-type="bibr" rid="B42">Wei Tan et al., 2020</xref>). Therefore, we set out to examine the bacterial uptake rates of Au1 and auranofin using inductively coupled plasma mass spectrometry (ICP-MS). Unexpectedly, both the auranofin and Au1 could be efficiently uptaken by <italic>P. aeruginosa</italic> with a final cellular concentration of approximately 40&#xa0;ng/mg bacterial wet weight. Typically, auranofin even had a faster uptake rate compared to Au1 (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Further subcellular distribution analysis indicated that vast majority of the two compounds were located in the cytoplasm and only a tiny fraction remained on the bacterial membrane (<xref ref-type="fig" rid="F2">Figure 2B</xref>). The results showed that the high bactericidal activity of Au1 was not associated with its uptake. Moreover, a recent study demonstrated that auranofin could synergize with antibiotics on killing pathogenic bacteria (<xref ref-type="bibr" rid="B38">Sun et al., 2020</xref>). Encouragingly, similar synergistic effects were also observed between Au1 and two antibiotics used in clinic (tobramycin and colistin), suggesting that the Au1 could also be used as an adjuvant for antibiotic therapy (<xref ref-type="sec" rid="s11">Supplementary Figure S4</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Kinetics of Au1 and auranofin uptake by <italic>P. aeruginosa</italic>. <bold>(B)</bold> Subcellular distribution of Au contents in bacteria after Au1 or auranofin treatment <bold>(C)</bold> Bacterial resistance studies of Au1, ciprofloxacin and tobramycin clinical against <italic>P. aeruginosa</italic>. The inhibition of bacterial pyocyanin <bold>(D)</bold>, pyoverdine <bold>(E)</bold>, LasA protease <bold>(F)</bold>, elastase <bold>(G)</bold> and biofilm formation <bold>(H)</bold> by Au1 compound with different concentrations. All experiments are performed in triplicated and data are presented as mean &#xb1; sd. &#x2a; means <italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a; means <italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a; means <italic>p</italic> &#x3c; 0.001.</p>
</caption>
<graphic xlink:href="fchem-10-895159-g002.tif"/>
</fig>
<p>Since antimicrobial resistance is a major concern for the development of antibacterial regents, resistance development experiments were then employed to examine the bacterial resistance to Au1. And two antibiotics ciprofloxacin and tobramycin were used as control. As shown in <xref ref-type="fig" rid="F2">Figure 2C</xref>, development of resistance to Au1 was not observed after a serial passage of <italic>P. aeruginosa</italic> in the presence of sub-lethal concentrations of Au-1 over 14&#xa0;days. In contrast, the MIC values of ciprofloxacin and tobramycin both increased by 30 times over 14&#xa0;days. The result indicates that continuous treatment of Au1 would not lead to the development of resistance by <italic>P. aeruginosa</italic>.</p>
<p>
<italic>P. aeruginosa</italic> expresses numerous virulence factors that not only accelerate bacterial colonization but also elude immune clearance by the host. Previous studies showed that auranofin effectively attenuated the virulence factors expression of <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B42">Wei Tan et al., 2020</xref>). Given the high bactericidal activity of Au1, we subsequently examined the effects of Au1 on the bacterial virulence factors expression. <italic>P. aeruginosa</italic> bacterial culture was incubated with gradient concentrations of <bold>Au1</bold> that are sub-lethal to the bacteria. The inhibitory effects of Au1 on the pyocyanin, pyoverdine, LasA protease, and LasB elastase of <italic>P. aeruginosa</italic> were shown in <xref ref-type="fig" rid="F2">Figures 2D&#x2013;G</xref>. Pyocyanin is a secondary metabolite secreted by <italic>P. aeruginosa</italic> is able to target a wide range of cellular pathways and therefore can kill mammalian lung cells upon bacterial infection (<xref ref-type="bibr" rid="B22">Lau et al., 2004</xref>). The secreted pyocyanin was significantly reduced after incubation with Au1. Typically, the pyocyanin secretion was almost completely inhibited in the presence of 15&#xa0;&#x3bc;M Au1. Similarly, the secretion of LasA protease, elastase and pyoverdine siderophore were also decreased by 54, 38, and 50% respectively after incubation with 15&#xa0;&#x3bc;M Au1. Moreover, rhamnolipid is a unique class of glycolipid produced by <italic>P. aeruginosa</italic>. Previous study showed that rhamnolipid is the only identified virulence factor that was associated with the deterioration of the patients to ventilator-associated pneumonia in hospital (<xref ref-type="bibr" rid="B41">Wagener et al., 2021</xref>). Both the auranofin and Au1 (15&#xa0;&#x3bc;M<bold>)</bold> could significantly suppress the synthesis of rhamnolipid (<xref ref-type="sec" rid="s11">Supplementary Figure S5</xref>). Since the formation of rigorous biofilm is critical to the persistent infection of <italic>P. aeruginosa,</italic> we also examined whether Au1 has an effect on the formation of biofilms. Indeed, Au1 is sufficient to inhibit biofilm formation as low as 2.5&#xa0;&#x3bc;M (<xref ref-type="fig" rid="F2">Figure 2H</xref>). Collectively, all these results showed that the Au1 compound is a highly potent inhibitor to attenuate the virulence factor expression in <italic>P. aeruginosa</italic>.</p>
</sec>
<sec id="s3-3">
<title>Au1 Disrupts the Bacterial Membrane Integrity</title>
<p>The unexpected bactericidal activity of Au1 prompted us to further investigate its mechanism of action. We employed the field emission scanning electron microscope (FE-SEM) and atomic force microscopy (AFM) to visualize the morphological changes of <italic>P. aeruginosa</italic>. FE-SEM images showed that <italic>P. aeruginosa</italic> exhibited wrinkling and collapsed structures after the treatment of Au1, resulting in a rough bacterial surface with clear bumps and valleys. In contrast, no significant changes were observed in the auranofin-treated group (<xref ref-type="fig" rid="F3">Figure 3A</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S6</xref>). To further characterize the change of bacterial membrane after treatment, AFM was employed to measure the bacterial surface roughness (<xref ref-type="fig" rid="F3">Figure 3A</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S7</xref>). In consistent with the FE-SEM results, the root-mean-square roughness (R<sub>q</sub>) of the bacterial surface after Au1 treatment was determined to be 10.5 &#xb1; 1.5&#xa0;nm, which is significantly larger than that in the control (4.5 &#xb1; 0.3&#xa0;nm) and auranofin treated groups (3.8 &#xb1; 0.7&#xa0;nm) (<xref ref-type="fig" rid="F3">Figure 3B</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> FE-SEM and AFM analysis of the morphology of <italic>P. aeruginosa</italic> after incubation with Au1 or auranofin. <bold>(B)</bold> Quantification of the root-mean-square roughness (R<sub>q</sub>) of the bacterial surface. All experiments are performed in triplicated and data are presented as mean &#xb1; sd. &#x2a;&#x2a;&#x2a; means <italic>p</italic> &#x3c; 0.001. <bold>(C)</bold> Flow cytometry analysis of the bacterial membrane permeability after incubation with auranofin, Au1 and polymyxin B. Blue colour represents the counted cell with impermeable membrane, and red colour represents the cell with permeable membrane.</p>
</caption>
<graphic xlink:href="fchem-10-895159-g003.tif"/>
</fig>
<p>The significant change of bacterial surface roughness after Au1 treatment implied that the gold compound might damage the physiological function of bacterial membrane. Therefore, we further examined the bacterial permeability after treatment with Au1 or auranofin. In brief, log-phase <italic>P. aeruginosa</italic> was incubated with 50&#xa0;&#x3bc;M auranofin, Au1 or 5&#xa0;&#x3bc;M polymyxin B for 30&#xa0;min followed by staining with propidium iodide (PI) dye to monitor the bacterial permeability change. Since the PI is membrane-impermeable and is generally excluded from viable cells, cells with increased permeability will produce a higher fluorescence signal than control cells. As shown in <xref ref-type="fig" rid="F3">Figure 3C</xref>, auranofin treatment did not significantly affect the bacterial fluorescence signal when compared with the control group. Whereas, the treatment of polymyxin B, an antibiotic that targets and destabilizes bacterial outer membrane, remarkably increased the bacterial fluorescence signals. Similar fluorescence incensement was also observed in Au1 treated <italic>P. aeruginosa</italic>, indicative of enhanced bacterial membrane permeability. Moreover, we further investigated the kinetics of the bacterial membrane permeation caused by Au1 compound. <italic>P. aeruginosa</italic> bacteria were incubated in M9 medium supplemented with PI dye and different concentrations of Au1 or auranofin were added into the medium. Time-course of the fluorescence signals (561&#xa0;nm ex, 590&#xa0;nm em) were monitored on a microplate reader. The results showed that the initiation of bacterial membrane rupture occurred after 1.5&#xa0;h when incubated with 50&#xa0;&#x3bc;M Au1 at 37&#xb0;C (<xref ref-type="sec" rid="s11">Supplementary Figure S8</xref>). Collectedly, all the results clearly indicated that Au1 could disrupt the bacterial membrane integrity, and thereby leading to bacterial death.</p>
</sec>
<sec id="s3-4">
<title>Transcriptomic Analysis</title>
<p>Subsequently, we further investigated the antibacterial mechanism of Au1 on <italic>P. aeruginosa</italic> at the transcriptome levels using auranofin as a control. For transcriptomic analysis, log-phase <italic>P. aeruginosa</italic> was treated with 15&#xa0;&#x3bc;M Au1 or auranofin for 4&#xa0;h, from which good quality RNA were extracted, indicating that the bacteria were not severely damaged. Compared to the control group, the transcriptional levels of 680 genes were significantly altered by Au1 treatment, among which 381 and 299 genes were up- and down-regulated, respectively. Whereas, auranofin caused larger fluctuations in gene transcriptional levels than Au1 did, leading to a change of 1,512 gene, including 778 genes up-regulated, and 734 genes down-regulated (<xref ref-type="fig" rid="F4">Figure 4A</xref>; <xref ref-type="sec" rid="s11">Supplementary Figure S9</xref>). The significantly altered genes in Au1 and auranofin treated groups were analyzed according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Several KEGG pathways were identified in both Au1 and auranofin treated groups, such as ABC transporters, quorum sensing and starch and sucrose metabolism (<xref ref-type="sec" rid="s11">Supplementary Figure S10</xref>). Unexpectedly, further analysis revealed different changes of the genes involved in the starch and sucrose metabolism pathway, i.e., the transcriptional levels of these genes were prominently up-regulated in auranofin-treated group, but down-regulated in Au1-treated group (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The starch and sucrose metabolism pathway is mainly responsible for the biosynthesis of glycogen and trehalose (<xref ref-type="fig" rid="F4">Figure 4C</xref>). Since trehalose is essential for bacterial membranes stabilization under adverse stress conditions, this may at least partially explain why Au1 could severely damage bacterial membrane (<xref ref-type="bibr" rid="B7">Cross et al., 2018</xref>; <xref ref-type="bibr" rid="B21">Kim et al., 2021</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>
<bold>(A)</bold> Venn diagrams showing the number of up- and down-regulated genes in the Au1 and auarnofin treated groups compared to the control group. <bold>(B)</bold> KEGG analysis reveal enrichment pathways that completely opposites under the treatment of Au1 and Auranofin (left panel represents auranofin-treated group, right panel represents Au1-treated group). <bold>(C)</bold> Starch and sucrose metabolism pathway and the heat map for relative genes of <italic>P. aeruginosa</italic> in the Au1 and auranofin treated groups. <bold>(D)</bold> Riboflavin biosynthesis pathway and the heat map for relative genes of <italic>P. aeruginosa</italic> in the Au1 and auranofin treated groups.</p>
</caption>
<graphic xlink:href="fchem-10-895159-g004.tif"/>
</fig>
<p>Since Au1 and auranofin exhibited different bactericidal activities, implying the two compounds should have distinct mechanism of actions. Transcriptomic analysis revealed that totally 73 KEGG pathways were both significantly perturbed by Au1 and auranofin, among which 44 pathways were affected by auranofin alone and 6 pathways were affected by Au1 alone (<xref ref-type="sec" rid="s11">Supplementary Figure S11</xref>). Intriguingly, among the six pathways that are solely affected by Au1, four are related to the degradation of benzene homologues, one is related to sphingolipid metabolism and the last one is related to riboflavin metabolism. Riboflavin has an essential role in oxidative metabolism for all organisms. Particularly, it is also involved in quorum sensing signaling processes in bacteria (<xref ref-type="bibr" rid="B25">Li et al., 2021</xref>). The Au1 treatment significantly down-regulated the transcriptional level of <italic>hpaC</italic> and <italic>msuE</italic> genes, which encode the reductase involved in flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) biosynthesis (<xref ref-type="fig" rid="F4">Figure 4D</xref>). The results implied that the abrogation of the essential riboflavin metabolism pathway may contribute to the high bactericidal activity of Au1.</p>
</sec>
<sec id="s3-5">
<title>Mammalian and Bacterial Cells Co-Culture Experiment</title>
<p>
<italic>P. aeruginosa</italic> is known to cause a cytotoxic effect on eukaryotic cell via translocation of bacterial effectors into the host cells (<xref ref-type="bibr" rid="B34">Meirelles and Newman, 2018</xref>; <xref ref-type="bibr" rid="B32">Malhotra et al., 2019</xref>). To further explore the potential application of Au1 in treatment of infections caused by <italic>P. aeruginosa</italic>, a mammalian and bacterial cell co-culture experiment was performed to mimic the bacterial infection <italic>in vitro</italic>. In brief, the human alveolar basal epithelial A549 cells were co-cultured with <italic>P. aeruginosa</italic> PAO1 strain (the ratio of bacteria to cells is 50:1) in the absence or presence of Au1 compound. The cytotoxic effects of <italic>P. aeruginosa</italic> were examined based on A549 cell morphology after 2&#xa0;h incubation. As shown in <xref ref-type="fig" rid="F5">Figure 5</xref>, healthy A549 cell exhibited a pebble-like shape and formed well spread monolayer. Once co-cultured with <italic>P. aeruginosa</italic>, majority of A549 cells retracted into round shapes with drastically reduced surface area and gradually detached from the culture plate. Encouragingly, the cytotoxic effects of <italic>P. aeruginosa</italic> on A549 cells were substantially attenuated with the increasing concentrations of <bold>Au1</bold> compound. Approximately 20&#xa0;&#x3bc;M Au1 complex was sufficient to protect A549 cells from the <italic>P. aeruginosa</italic> bacterial cytotoxicity. While as high as 30&#xa0;&#x3bc;M Au1 alone had no significant effects on A549 cell morphology.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Bacterial and mammalian cell co-culture experiment. Human alveolar basal epithelial A549 cells are incubated with <italic>P. aeruginosa</italic> in the absence and presence of different concentrations of Au1 compound. Scale bar: 100&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fchem-10-895159-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Au1 Eradicates <italic>P. aeruginosa</italic> in Mouse Skin Infection Model</title>
<p>The above results promoted us to further investigate whether the Au1 compound was also efficacious in an <italic>in vivo</italic> animal infection model. To this end, we used a mouse wound infection model to assess the anti-<italic>P. aeruginosa</italic> efficacy of Au1 as described previously (<xref ref-type="bibr" rid="B27">Liao et al., 2017b</xref>). In brief, a circular wound with a diameter of 6&#xa0;mm was created on the flank of mice, and approximately 5 &#xd7; 10<sup>8</sup> CFU of <italic>P. aeruginosa</italic> PAO1 were dipped onto the wound by medical cotton swab to induce infection. Treatment is administered on the 1st day with auranofin or Au1 compound (50&#xa0;&#x3bc;M, 20&#xa0;&#x3bc;L) was applied to the wounds. The wound sizes and mice weights were recorded each day. On the 8th day, the infection sites were excised and part of the tissues was fixed in 4% paraformaldehyde and embedded in paraffin. Four-micrometer sections were cut, stained with Gram, H&#x26;E, and Masson&#x2019;s trichrome stain. The remained tissues were homogenized and serially diluted for CFU quantification (<xref ref-type="fig" rid="F6">Figure 6A</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>
<bold>(A)</bold> Schematic illustration of the mice infection experiment. <bold>(B)</bold> The representative images and curves <bold>(C)</bold> of wound areas of control, aranofin-, and Au1-treated groups. Scale bar: 5&#xa0;mm. <bold>(D)</bold> Mice weight changes within 8&#xa0;days in various experimental groups. <bold>(E)</bold> The representative images and quantification of <italic>P. aeruginosa</italic> bacteria in the mice wounds. All experiments are performed in triplicated and data are presented as mean &#xb1; sd. &#x2a; means <italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;&#x2a;&#x2a;means <italic>p</italic> &#x3c; 0.0001. <bold>(F)</bold> Gram, H&#x26;E and Masson&#x2019;s trichrome staining of mice wound tissues in various experimental groups. Scale bar: 500&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fchem-10-895159-g006.tif"/>
</fig>
<p>As shown in <xref ref-type="fig" rid="F6">Figures 6B, C</xref>, the wound healing rate in the Au1-treated group was much faster than that in the auranofin-treated group or control group. In particular, the infected wound was almost completely recovered on the 8th day after Au1 treatment. In addition, there were no significant changes in the mice weights in all the three experimental groups, indicating that the application of Au1 or auranofin exhibited no significant toxicity to the mice (<xref ref-type="fig" rid="F6">Figure 6D</xref>). The quantification of bacterial CUF in the infection sites showed that the Au1 treatment significantly reduced the live bacteria by 90% when compared to that in the control group. Whereas, approximately 70% of bacteria remained live in the auranofin-treated group (<xref ref-type="fig" rid="F6">Figure 6E</xref>).</p>
<p>In addition, we performed histological analyses of the infected tissue to further assess the wound healing (<xref ref-type="fig" rid="F6">Figure 6F</xref>). Gram staining results showed the presence of a large number of bacteria in the infected wound tissue in the control and auranofin-treated groups (blue colour indicates the presence of bacteria). In contrast, no bacteria was observed in Au1-treated wounds, indicative of the remarkable antibacterial effect of Au1. At the same time, H&#x26;E staining results showed that scabs grew in the wound of the control and auranofin-treated groups, while the wound epidermis of the Au1 group tended to be intact. Moreover, hair follicles began to appear in the wounds of the Au1 group, indicating that the wounds were healed. Masson staining results indicated the formation of blue-stained collagen fibers in different groups. The deposition of collagen fibers in the Au1 group was significantly better than that in the control and auranofin groups. The above results further indicated that Au1 had good antibacterial activity <italic>in vivo</italic> and promoted wound healing.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>In summary, we reported a gold(I) carbene compound, named as Au1, with excellent bactericidal activity against human pathogenic bacteria <italic>P. aeruginosa. In vitro</italic> studies showed that Au1 also has broad-spectrum antibacterial properties towards a panel of Gram-negative and -positive bacteria. Unlike antibiotics, continuous exposure of <italic>P. aeruginosa</italic> to Au1 compound does not induce drug resistance. At sub-lethal concentrations, Au1 substantially attenuates the virulence expression of <italic>P. aeruginosa</italic> and exhibits synergistic effects with antibiotics to inhibit bacterial growth. FE-SEM and AFM analysis of the <italic>P. aeruginosa</italic> bacteria reveals that Au1 treatment disrupts the bacterial membrane integrity, and thereby leading to significantly morphological changes of <italic>P. aeruginosa</italic> cell. Further RNA-seq results reveals Au1 could severely perturb several pathways in <italic>P. aeruginosa</italic>. In particular, the transcriptional levels of genes involved in riboflavin and trehalose biosynthesis are remarkably down-regulated by Au1. Since riboflavin derivatives are essential cofactors for a myriad of enzymes and trehalose is required for bacterial membrane stabilization, the bactericidal activity of Au1 could be partially attributed to the perturbation of the two essential bacterial metabolism pathways. Finally, we further verified that Au1 could efficiently eradicate <italic>P. aeruginosa</italic> in a mouse skin infection model. In a word, our studies demonstrate that the Au1 compound has great potential as a novel antibacterial agent for future clinical application to cope with current crisis of antimicrobial resistance.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are publicly available. This data can be found here: <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena/browser/view/">https://www.ebi.ac.uk/ena/browser/view/</ext-link>, PRJEB51645.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Animal Ethics Committee of Wen-zhou Medical University (SYXK-2021-0020).</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>JW, TZ, WX and Z-WM conceived and designed the experiments. WX and Z-WM coordinated the whole study. The experiments were carried out by JW, XS, YX, YL, HC, and XH, WX and Z-WM analyzed the data. The manuscript was written through contributions from all authors. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This work was supported by the National Natural Science Foundation of China (22022706, 21877131, and 91953117), Natural Science Foundation of Guangdong Province, China (2019A1515011156), the Ministry of Education of China (IRT-17R111), and the Fundamental Research Funds for the Central Universities.</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchem.2022.895159/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchem.2022.895159/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Barnard</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Berners-Price</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Brayshaw</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Hickey</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Skelton</surname>
<given-names>B. W.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Synthesis and Structural Characterisation of Linear Au(I) N-Heterocyclic Carbene Complexes: New Analogues of the Au(I) Phosphine Drug Auranofin</article-title>. <source>J. Organomet. Chem.</source> <volume>690</volume> (<issue>24</issue>), <fpage>5625</fpage>&#x2013;<lpage>5635</lpage>. <pub-id pub-id-type="doi">10.1016/j.jorganchem.2005.07.013</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berners-Price</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Sadler</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Gold(I) Complexes with Bidentate Tertiary Phosphine Ligands: Formation of Annular vs. Tetrahedral Chelated Complexes</article-title>. <source>Inorg. Chem.</source> <volume>25</volume> (<issue>21</issue>), <fpage>3822</fpage>&#x2013;<lpage>3827</lpage>. <pub-id pub-id-type="doi">10.1021/ic00241a023</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Botelho</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grosso</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Peixe</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Antibiotic Resistance in <italic>Pseudomonas aeruginosa</italic> - Mechanisms, Epidemiology and Evolution</article-title>. <source>Drug Resist. Updates</source> <volume>44</volume>, <fpage>100640</fpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2019.07.002</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breijyeh</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jubeh</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karaman</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve it</article-title>. <source>Molecules</source> <volume>25</volume> (<issue>6</issue>), <fpage>1340</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25061340</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Che</surname>
<given-names>C.-M.</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>C.-K.</given-names>
</name>
<name>
<surname>Yam</surname>
<given-names>V. W.-W.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>ChemInform Abstract: Spectroscopy and Redox Properties of the Luminescent Excited State of (Au<sub>2</sub>(dppm)<sub>2</sub>)<sup>2&#x2b;</sup> (Dppm: Ph<sub>2</sub>PCH<sub>2</sub>PPh<sub>2</sub>)</article-title>. <source>ChemInform</source> <volume>22</volume> (<issue>6</issue>), <fpage>80</fpage>. <pub-id pub-id-type="doi">10.1002/chin.199106080</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chernousova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Epple</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Silver as Antibacterial Agent: Ion, Nanoparticle, and Metal</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>52</volume> (<issue>6</issue>), <fpage>1636</fpage>&#x2013;<lpage>1653</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201205923</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cross</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biberacher</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Rajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Korhonen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>R. B.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Trehalose 6&#x2010;phosphate Phosphatases of <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>FASEB J.</source> <volume>32</volume> (<issue>10</issue>), <fpage>5470</fpage>&#x2013;<lpage>5482</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201800500R</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essar</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Eberly</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hadero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>I. P.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Identification and Characterization of Genes for a Second Anthranilate Synthase in <italic>Pseudomonas aeruginosa</italic>: Interchangeability of the Two Anthranilate Synthases and Evolutionary Implications</article-title>. <source>J. Bacteriol.</source> <volume>172</volume> (<issue>2</issue>), <fpage>884</fpage>&#x2013;<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1128/jb.172.2.884-900.1990</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischbach</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Malfertheiner</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Helicobacter Pylori Infection</article-title>. <source>Dtsch Arztebl. Int.</source> <volume>115</volume> (<issue>25</issue>), <fpage>429</fpage>&#x2013;<lpage>436</lpage>. <pub-id pub-id-type="doi">10.3238/arztebl.2018.0429</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zuegg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Braese</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Metal Complexes as a Promising Source for New Antibiotics</article-title>. <source>Chem. Sci.</source> <volume>11</volume> (<issue>10</issue>), <fpage>2627</fpage>&#x2013;<lpage>2639</lpage>. <pub-id pub-id-type="doi">10.1039/c9sc06460e</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>W.-F.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Miskowski</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>C.-M.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The Intrinsic3[d&#x3c3;&#x2a;p&#x3c3;] Emission of Binuclear Gold(I) Complexes with Two Bridging Diphosphane Ligands Lies in the Near UV; Emissions in the Visible Region Are Due to Exciplexes</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>38</volume> (<issue>18</issue>), <fpage>2783</fpage>&#x2013;<lpage>2785</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1521-3773(19990917)38:18&#x3c;2783::aid-anie2783&#x3e;3.0.co;2-i</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasser</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Metzler-Nolte</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The Potential of Organometallic Complexes in Medicinal Chemistry</article-title>. <source>Curr. Opin. Chem. Biol.</source> <volume>16</volume> (<issue>1-2</issue>), <fpage>84</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2012.01.013</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habets</surname>
<given-names>M. G. J. L.</given-names>
</name>
<name>
<surname>Brockhurst</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Therapeutic Antimicrobial Peptides May Compromise Natural Immunity</article-title>. <source>Biol. Lett.</source> <volume>8</volume> (<issue>3</issue>), <fpage>416</fpage>&#x2013;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1098/rsbl.2011.1203</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Multi-omics and Temporal Dynamics Profiling Reveal Disruption of central Metabolism inHelicobacter Pylorion Bismuth Treatment</article-title>. <source>Chem. Sci.</source> <volume>9</volume> (<issue>38</issue>), <fpage>7488</fpage>&#x2013;<lpage>7497</lpage>. <pub-id pub-id-type="doi">10.1039/c8sc01668b</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harbut</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Vilch&#xe8;ze</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hensler</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Auranofin Exerts Broad-Spectrum Bactericidal Activities by Targeting Thiol-Redox Homeostasis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>112</volume> (<issue>14</issue>), <fpage>4453</fpage>&#x2013;<lpage>4458</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1504022112</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Bismuth-Induced Inactivation of Ferric Uptake Regulator from <italic>Helicobacter pylori</italic>
</article-title>. <source>Inorg. Chem.</source> <volume>56</volume> (<issue>24</issue>), <fpage>15041</fpage>&#x2013;<lpage>15048</lpage>. <pub-id pub-id-type="doi">10.1021/acs.inorgchem.7b02380</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernando-Amado</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sanz-Garc&#xed;a</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mart&#xed;nez</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Rapid and Robust Evolution of Collateral Sensitivity in <italic>Pseudomonas aeruginosa</italic> Antibiotic-Resistant Mutants</article-title>. <source>Sci. Adv.</source> <volume>6</volume> (<issue>32</issue>), <fpage>eaba5493</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aba5493</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hickey</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Ruhayel</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Barnard</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Berners-Price</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Filipovska</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Mitochondria-targeted Chemotherapeutics: the Rational Design of Gold(I) N-Heterocyclic Carbene Complexes that Are Selectively Toxic to Cancer Cells and Target Protein Selenols in Preference to Thiols</article-title>. <source>J. Am. Chem. Soc.</source> <volume>130</volume> (<issue>38</issue>), <fpage>12570</fpage>&#x2013;<lpage>12571</lpage>. <pub-id pub-id-type="doi">10.1021/ja804027j</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Igashira-Kamiyama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Itai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Bis[&#x3bc;-1,3-bis(diphenylphosphanyl)propane-&#x3ba;<sup>2</sup>P:P&#x2032;]Digold(I) Tetrachloridonickelate(II) Diethyl Ether Monosolvate</article-title>. <source>Acta Cryst E</source> <volume>69</volume> (<issue>6</issue>)<bold>,</bold> <fpage>m339</fpage>. <pub-id pub-id-type="doi">10.1107/S1600536813013470</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>J&#xfc;rg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Paolo</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Interaction of Antibacterial Compounds with RND Efflux Pumps in <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Front. Microbiol.</source> <volume>6</volume>, <fpage>660</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00660</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hofmann</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Characterisation of Trehalose-6-Phosphate Phosphatases from Bacterial Pathogens</article-title>. <source>Biochim. Biophys. Acta Proteins Proteomics</source> <volume>1869</volume> (<issue>2</issue>), <fpage>140564</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2020.140564</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hassett</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Mavrodi</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>
<italic>Pseudomonas aeruginosa</italic> Pyocyanin Is Critical for Lung Infection in Mice</article-title>. <source>Infect. Immun.</source> <volume>72</volume> (<issue>7</issue>), <fpage>4275</fpage>&#x2013;<lpage>4278</lpage>. <pub-id pub-id-type="doi">10.1128/Iai.72.7.4275-4278.2004</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>
<italic>Pseudomonas aeruginosa</italic> Biofilm, a Programmed Bacterial Life for Fitness</article-title>. <source>J. Microbiol. Biotechnol.</source> <volume>27</volume> (<issue>6</issue>), <fpage>1053</fpage>&#x2013;<lpage>1064</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1611.11056</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levin</surname>
<given-names>J. Z.</given-names>
</name>
<name>
<surname>Yassour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adiconis</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Nusbaum</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Comprehensive Comparative Analysis of Strand-specific RNA Sequencing Methods</article-title>. <source>Nat. Methods</source> <volume>7</volume> (<issue>9</issue>), <fpage>709</fpage>&#x2013;<lpage>715</lpage>. <pub-id pub-id-type="doi">10.1038/Nmeth.1491</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W. R.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X. B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Diallyl Sulfide from Garlic Suppresses Quorum&#x2010;sensing Systems of <italic>Pseudomonas aeruginosa</italic> and Enhances Biosynthesis of Three B Vitamins through its Thioether Group</article-title>. <source>Microb. Biotechnol.</source> <volume>14</volume> (<issue>2</issue>), <fpage>677</fpage>&#x2013;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1111/1751-7915.13729</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>So</surname>
<given-names>P.-K.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Targeting the Thioredoxin Reductase-Thioredoxin System from <italic>Staphylococcus aureus</italic> by Silver Ions</article-title>. <source>Inorg. Chem.</source> <volume>56</volume> (<issue>24</issue>), <fpage>14823</fpage>&#x2013;<lpage>14830</lpage>. <pub-id pub-id-type="doi">10.1021/acs.inorgchem.7b01904</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>R. Y. T.</given-names>
</name>
<etal/>
</person-group> (<year>2017b</year>). <article-title>Identification of Catabolite Control Protein A fromStaphylococcus Aureusas a Target of Silver Ions</article-title>. <source>Chem. Sci.</source> <volume>8</volume> (<issue>12</issue>), <fpage>8061</fpage>&#x2013;<lpage>8066</lpage>. <pub-id pub-id-type="doi">10.1039/c7sc02251d</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>A. S. C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R. W. Y.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Bioorthogonal Activation of Dual Catalytic and Anti&#x2010;Cancer Activities of Organogold(I) Complexes in Living Systems</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>60</volume> (<issue>8</issue>), <fpage>4133</fpage>&#x2013;<lpage>4141</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202013366</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe Streptococcus Suis Infections</article-title>. <source>Antibiotics (Basel)</source> <volume>10</volume> (<issue>1</issue>), <fpage>26</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics10010026</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lund-Palau</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bardin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cameron</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Soren</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Pseudomonas Aeruginosainfection in Cystic Fibrosis: Pathophysiological Mechanisms and Therapeutic Approaches</article-title>. <source>Expert Rev. Respir. Med.</source> <volume>10</volume> (<issue>6</issue>), <fpage>685</fpage>&#x2013;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1080/17476348.2016.1177460</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mah</surname>
<given-names>T.-F.</given-names>
</name>
<name>
<surname>Pitts</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pellock</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>O&#x27;Toole</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>A Genetic Basis for <italic>Pseudomonas aeruginosa</italic> Biofilm Antibiotic Resistance</article-title>. <source>Nature</source> <volume>426</volume> (<issue>6964</issue>), <fpage>306</fpage>&#x2013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1038/nature02122</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>D.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Wozniak</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cystic Fibrosis and <italic>Pseudomonas aeruginosa</italic>: the Host-Microbe Interface</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>32</volume> (<issue>3</issue>), <fpage>e00138</fpage>. <pub-id pub-id-type="doi">10.1128/cmr.00138-18</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Sheehan</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Bratton</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S. H.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance</article-title>. <source>Cell</source> <volume>181</volume> (<issue>7</issue>), <fpage>1518</fpage>&#x2013;<lpage>1532</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.005</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meirelles</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>D. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Both toxic and Beneficial Effects of Pyocyanin Contribute to the Lifecycle of <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Mol. Microbiol.</source> <volume>110</volume> (<issue>6</issue>), <fpage>995</fpage>&#x2013;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.14132</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitcheltree</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Pisipati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Syroegin</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Silvestre</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Klepacki</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>J. D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A Synthetic Antibiotic Class Overcoming Bacterial Multidrug Resistance</article-title>. <source>Nature</source> <volume>599</volume> (<issue>7885</issue>), <fpage>507</fpage>&#x2013;<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04045-6</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morihara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsuzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Oka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ebata</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1965</year>). <article-title>
<italic>Pseudomonas aeruginosa</italic> Elastase</article-title>. <source>J. Biol. Chem.</source> <volume>240</volume>, <fpage>3295</fpage>&#x2013;<lpage>3304</lpage>. <pub-id pub-id-type="doi">10.1016/S0021-9258(18)97217-0</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shteinberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Haq</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Polineni</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cystic Fibrosis</article-title>. <source>Lancet</source> <volume>397</volume> (<issue>10290</issue>), <fpage>2195</fpage>&#x2013;<lpage>2211</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)32542-3</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>Y.-T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Resensitizing Carbapenem- and Colistin-Resistant Bacteria to Antibiotics Using Auranofin</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>5263</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-18939-y</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thangamani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Abushahba</surname>
<given-names>M. F. N.</given-names>
</name>
<name>
<surname>Sobreira</surname>
<given-names>T. J. P.</given-names>
</name>
<name>
<surname>Hedrick</surname>
<given-names>V. E.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>L. N.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Antibacterial Activity and Mechanism of Action of Auranofin against Multi-Drug Resistant Bacterial Pathogens</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>22571</fpage>. <pub-id pub-id-type="doi">10.1038/srep22571</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verch&#xe8;re</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dezi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adrien</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Broutin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>
<italic>In Vitro</italic> transport Activity of the Fully Assembled MexAB-OprM Efflux Pump from <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>Nat. Commun.</source> <volume>6</volume> (<issue>1</issue>), <fpage>6890</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7890</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagener</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pittet</surname>
<given-names>J.-F.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Role of <italic>Pseudomonas aeruginosa</italic> Virulence Factors in Cytoskeletal Dysregulation and Lung Barrier Dysfunction</article-title>. <source>Toxins</source> <volume>13</volume> (<issue>11</issue>), <fpage>776</fpage>. <pub-id pub-id-type="doi">10.3390/toxins13110776</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei Tan</surname>
<given-names>L. Z.</given-names>
</name>
<name>
<surname>Hoong Yam</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Santillan Salido</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>B. Y.</given-names>
</name>
<name>
<surname>Yau Li</surname>
<given-names>S. F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Auranofin Inhibits Virulence in <italic>Pseudomonas aeruginosa</italic>
</article-title>. <source>bioRxiv</source>, <fpage>198820</fpage>. <pub-id pub-id-type="doi">10.1101/198820</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiegand</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hilpert</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>R. E. W.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Agar and Broth Dilution Methods to Determine the Minimal Inhibitory Concentration (MIC) of Antimicrobial Substances</article-title>. <source>Nat. Protoc.</source> <volume>3</volume> (<issue>2</issue>), <fpage>163</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2007.521</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Metelitsa</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A. N.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Pseudomonas Skin Infection</article-title>. <source>Am. J. Clin. Dermatol.</source> <volume>12</volume> (<issue>3</issue>), <fpage>157</fpage>&#x2013;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.2165/11539770-000000000-00000</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Z. W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Light&#x2010;Triggered Nitric Oxide Release by a Photosensitizer to Combat Bacterial Biofilm Infections</article-title>. <source>Chem. Eur. J.</source> <volume>27</volume> (<issue>17</issue>), <fpage>5453</fpage>&#x2013;<lpage>5460</lpage>. <pub-id pub-id-type="doi">10.1002/chem.202004698</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lum</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Lok</surname>
<given-names>C.-N.</given-names>
</name>
<name>
<surname>To</surname>
<given-names>W.-P.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>C.-M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A Binuclear Gold(I) Complex with Mixed Bridging Diphosphine and bis(N-Heterocyclic Carbene) Ligands Shows Favorable Thiol Reactivity and Inhibits Tumor Growth and Angiogenesis <italic>In Vivo</italic>
</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>53</volume> (<issue>23</issue>), <fpage>5810</fpage>&#x2013;<lpage>5814</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201400142</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>